Clik here to view.
A new castration-resistant prostate cancer entity?
Brandon Manley, MDUT SUO 2015 Internship Member Profile Dr. Manley is a urologic oncology fellow at Memorial Sloan Kettering Cancer Center, New York. During the Society of Urologic Oncology 2015 winter...
View ArticleClik here to view.
What anti-PD-L1 immunotherapy approval means for urology
FDA approval of a new form of immunotherapy as well as a companion diagnostic test will have a significant impact on patients with the most common type of bladder cancer in the U.S., a leading...
View ArticleClik here to view.
Bladder Cancer: Androgen receptor activation a potential therapeutic target
Byron H. Lee, MD, PhDMultiple studies on exosomes, data from the IMvigor 210 trial of atezolizumab (TECENTRIQ), and research on prehabilitation for cystectomy were among the highlights in bladder...
View ArticleClik here to view.
Oral agent improves survival in advanced RCC patients
Chicago—Once-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor (TKI), significantly improves overall survival as well as progression-free survival and objective responses...
View ArticleImmunotherapies move toward FDA approval for urothelial Ca
Two investigational immunotherapy drugs, pembrolizumab (Keytruda) and nivolumab (Opdivo), are making progress toward FDA approval for treatment of urothelial carcinoma. Read: Next-gen sequencing panel...
View ArticleNext-gen sequencing panel for renal Ca earns CLIA approval
Focus::Renal (Cancer Genetics), a genomic profiling tool covering most renal cancer markers and pathways, has earned Clinical Laboratory Improvement Amendments (CLIA) validation and approval,...
View ArticleHigh-grade bladder Ca: New data improve risk stratification
At the Society of Urologic Oncology annual meeting in San Antonio, Joaquim Bellmunt, MD, PhD, highlighted potential means to improve risk stratification in patients with high-grade T1 bladder cancer,...
View ArticleRCC: Multiple pathways provide therapeutic targets
The current state of targeted therapy and personalized medicine in renal cell carcinoma (RCC) is largely limited to the settings in which drugs were approved (first vs. later line) and the side effect...
View ArticlePCa immunotherapy: Response better when given before ADT
Administering sipuleucel-T (Provenge) before androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer appears to result in a more robust immunologic response...
View ArticleProstate Ca: Immunotherapy consensus statement published
The authors of the first evidence-based consensus statement on the use of immunotherapy to treat prostate cancer recommend using immunotherapy first, followed by an androgen receptor-targeted agent,...
View ArticleSmall molecule RNA inhibitor shows promise in PCa
New research demonstrates that targeted treatment with a class of drugs called small molecule RNA inhibitors can successfully target and kill certain types of cancer, including prostate cancer. In a...
View ArticleCombination immunotherapy may raise response rate in mRCC
Combination treatment built on immune checkpoint inhibitor therapy showed promising clinical and immunologic activity in patients with metastatic renal cell carcinoma (mRCC) in an early phase I...
View ArticleClik here to view.
Has the USPSTF gone far enough with its new PCa grade?
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.!doctype>
View ArticleShould RCC immunotherapy continue after progression?
Some patients being treated with nivolumab (Opdivo) for advanced renal cell carcinoma (RCC) may still derive benefit if continued on the immunotherapy agent after disease progression, according to a...
View ArticleUrothelial Ca immunotherapy approved for first-line use
Editor’s note: Shortly after this article was published online, Urology Times learned of an announcement by Roche regarding updated phase III study data on atezolizumab (Tecentriq) in individuals with...
View ArticleClik here to view.
Burnout, biopsy, BPH, and more: Post-AUA review
Henry Rosevear MDUT Blogger ProfileDr. Rosevear is a urologist in community practice in Colorado Springs, CO. I heard a lot of good lines at the AUA this year, including some with a unique Boston...
View ArticleImmunotherapy treats Ca based on genetic feature
The immunotherapy agent pembrolizumab (Keytruda) was recently approved by the FDA for treating any cancers that exhibit DNA mismatch repair deficiency, marking the first time the agency has approved a...
View ArticleClik here to view.
A promising target for immunotherapy?
Rosalyn M. Adam, PhDAmong the AUA annual meeting take-home messages in basic science is that the immune co-stimulatory molecule B7-H4 is highly expressed in the luminal subtype of bladder urothelial...
View ArticleProstate Ca immunotherapy induces T-cell response
Results of a study conducted to further elucidate the mechanism of action of sipuleucel-T (Provenge) as treatment for advanced prostate cancer provide fairly convincing demonstration that the...
View Article
